Psychedelics and Religious Freedom Joel Jay Finer
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Cultural Rights in the United States: a Conflict of Aluesv
Minnesota Journal of Law & Inequality Volume 5 Issue 2 Article 3 June 1987 Cultural Rights in the United States: A Conflict of aluesV Sharon O'Brien Follow this and additional works at: https://lawandinequality.org/ Recommended Citation Sharon O'Brien, Cultural Rights in the United States: A Conflict of aluesV , 5(2) LAW & INEQ. 267 (1987). Available at: https://scholarship.law.umn.edu/lawineq/vol5/iss2/3 Minnesota Journal of Law & Inequality is published by the University of Minnesota Libraries Publishing. Cultural Rights in the United States: A Conflict of Values Sharon O'Brien* Introduction ................................................... 268 I. Historical Development of Minority Rights ............. 270 Historical Examples of Pluralistic Arrangements ..... 271 International Protection of Group Rights ............. 273 Leading National Examples of Group Rights Protection ............................................. 279 Twentieth-Century Pluralist Thought ................. 281 The United States and the Rights of Minorities ...... 283 Available Constitutional Mechanisms ................. 287 II. Am erican Indians ....................................... 290 Historical Background and Assimilation Efforts ...... 290 Cultural Protection ................................... 296 Freedom of Religion .................................. 298 III. Native Hawaiians ........................................ 308 Historical Background ................................. 308 Cultural Protection ................................... 314 Protection of the -
From Sacred Plants to Psychotherapy
From Sacred Plants to Psychotherapy: The History and Re-Emergence of Psychedelics in Medicine By Dr. Ben Sessa ‘The rejection of any source of evidence is always treason to that ultimate rationalism which urges forward science and philosophy alike’ - Alfred North Whitehead Introduction: What exactly is it that fascinates people about the psychedelic drugs? And how can we best define them? 1. Most psychiatrists will define psychedelics as those drugs that cause an acute confusional state. They bring about profound alterations in consciousness and may induce perceptual distortions as part of an organic psychosis. 2. Another definition for these substances may come from the cross-cultural dimension. In this context psychedelic drugs may be recognised as ceremonial religious tools, used by some non-Western cultures in order to communicate with the spiritual world. 3. For many lay people the psychedelic drugs are little more than illegal and dangerous drugs of abuse – addictive compounds, not to be distinguished from cocaine and heroin, which are only understood to be destructive - the cause of an individual, if not society’s, destruction. 4. But two final definitions for psychedelic drugs – and those that I would like the reader to have considered by the end of this article – is that the class of drugs defined as psychedelic, can be: a) Useful and safe medical treatments. Tools that as adjuncts to psychotherapy can be used to alleviate the symptoms and course of many mental illnesses, and 1 b) Vital research tools with which to better our understanding of the brain and the nature of consciousness. Classifying psychedelic drugs: 1,2 The drugs that are often described as the ‘classical’ psychedelics include LSD-25 (Lysergic Diethylamide), Mescaline (3,4,5- trimethoxyphenylathylamine), Psilocybin (4-hydroxy-N,N-dimethyltryptamine) and DMT (dimethyltryptamine). -
Psilocybin Mushrooms Fact Sheet
Psilocybin Mushrooms Fact Sheet January 2017 What are psilocybin, or “magic,” mushrooms? For the next two decades thousands of doses of psilocybin were administered in clinical experiments. Psilocybin is the main ingredient found in several types Psychiatrists, scientists and mental health of psychoactive mushrooms, making it perhaps the professionals considered psychedelics like psilocybin i best-known naturally-occurring psychedelic drug. to be promising treatments as an aid to therapy for a Although psilocybin is considered active at doses broad range of psychiatric diagnoses, including around 3-4 mg, a common dose used in clinical alcoholism, schizophrenia, autism spectrum disorders, ii,iii,iv research settings ranges from 14-30 mg. Its obsessive-compulsive disorder, and depression.xiii effects on the brain are attributed to its active Many more people were also introduced to psilocybin metabolite, psilocin. Psilocybin is most commonly mushrooms and other psychedelics as part of various found in wild or homegrown mushrooms and sold religious or spiritual practices, for mental and either fresh or dried. The most popular species of emotional exploration, or to enhance wellness and psilocybin mushrooms is Psilocybe cubensis, which is creativity.xiv usually taken orally either by eating dried caps and stems or steeped in hot water and drunk as a tea, with Despite this long history and ongoing research into its v a common dose around 1-2.5 grams. therapeutic and medical benefits,xv since 1970 psilocybin and psilocin have been listed in Schedule I of the Controlled Substances Act, the most heavily Scientists and mental health professionals criminalized category for drugs considered to have a consider psychedelics like psilocybin to be “high potential for abuse” and no currently accepted promising treatments as an aid to therapy for a medical use – though when it comes to psilocybin broad range of psychiatric diagnoses. -
PSYCHEDELIC DRUGS (P.L) 1. Terminology “Hallucinogens
PSYCHEDELIC DRUGS (p.l) 1. Terminology “hallucinogens” – induce hallucinations, although sensory distortions are more common “psychotomimetics” – to minic psychotic states, although truly most drugs in this class do not do so “phantasticums”or “psychedelics” – alter sensory perception (Julien uses “psychedelics”) alterations in perception, cognition, and mood, in presence of otherwise clear ability to sense” may increase sensory awareness, increase clarity, decrease control over what is sensed/experienced “self-A” may feel a passive observer of what “self-B” is experiencing often accompanied by a sense of profound meaningfulness, of divine or cosmic importance (limbic system?) these drugs can be classified by what NT they mimic: anti-ACh, agonists for NE, 5HT, or glutamate (See p. 332, Table 12.l in Julien, 9th Ed.) 2. The Anti-ACh Psychedelics e.g. scopolamine (classified as an ACh blocker) high affinity, no efficacy plant product: Belladonna or “deadly nightshade” (Atropa belladonna) Datura stramonium (jimson weed, stinkweed) Mandragora officinarum (mandrake plant) pupillary dilation (2nd to atropine) PSYCHEDELIC DRUGS (p.2) 2. Anti-ACh Psychedelics (cont.) pharmacological effects: e.g. scopolamine (Donnatal) clinically used to tx motion sickness, relax smooth muscles (gastric cramping), mild sedation/anesthetic effect PNS effects --- dry mouth relaxation of smooth muscles decreased sweating increased body temperature blurred vision dry skin pupillary dilation tachycardia, increased BP CNS effects --- drowsiness, mild euphoria profound amnesia fatigue decreased attention, focus delirium, mental confusion decreased REM sleep no increase in sensory awareness as dose increases --- restlessness, excitement, hallucinations, euphoria, disorientation at toxic dose levels --- “psychotic delirium”, confusion, stupor, coma, respiratory depression so drug is really an intoxicant, amnestic, and deliriant 3. -
CLINICAL STUDY PROTOCOL Psilocybin-Assisted Psychotherapy
CLINICAL STUDY PROTOCOL Psilocybin-assisted Psychotherapy in the Management of Anxiety Associated With Stage IV Melanoma. Version: Final IND: [79,321] SPONSOR Multidisciplinary Association for Psychedelic PRINCIPAL INVESTIGATOR Sameet Kumar Ph.D. MEDICAL MONITOR Michael C. Mithoefer MD. STUDY PERSONNEL XXXXXXXXXXXXX XXXXXXXXXXXXX XXXXXXXXXXXXX STUDY MONITOR [CRA] Valerie Mojeiko IRB Study Site IRB Sponsor Signatory Rick Doblin Ph.D. Study Period 2008 For trial related emergencies please contact: Dr. Michael Mithoefer MAPS: S Kumar PI Clinical Study Protocol PCA1 Final December 1, 2007 Confidential Page 2 of 83 Table of Contents Introduction......................................................................................................................... 4 Background..................................................................................................................... 4 Disease History and Related Research ........................................................................... 5 Rationale ......................................................................................................................... 7 Summary......................................................................................................................... 7 Ethics................................................................................................................................... 8 Informed Consent of Subject .......................................................................................... 9 Recruitment and Screening............................................................................................ -
The Use of Psychedelic Drugs in the Treatment of Problematic Drug and Alcohol Use
Tripping up addiction: The use of psychedelic drugs in the treatment of problematic drug and alcohol use Short Title: Illicit drugs in the treatment of addiction Celia Morgan 1,3, Amy McAndrew1, Tobias Stevens1, David Nutt2, Will Lawn1,3 1. Psychopharmacology and Addiction Research Centre, University of Exeter, UK 2. Centre for Neuropsychopharmacology, Imperial College London, UK 3. Clinical Psychopharmacology Unit, University College London, UK Address Corrrespondence to: Celia Morgan Psychopharmacology and Addiction Research Centre Washington Singer Laboratory University of Exeter Perry Road, Exeter Devon UK EX4 4QG Key words: addiction, psychedelics, ketamine, ibogaine, ayahuasca, LSD , psilocybin, neurogenesis, 1 Highlights: Psilocybin may reduce alcohol and tobacco use in addicted samples. Ibogaine and ayahuasca have shown promise in the treatment of various addictions through observational studies. Ketamine has been used to treat alcohol dependence and reduces cocaine self- administration in the human laboratory. Randomised controlled trials are greatly needed to further test the efficacy of all of these compounds. Psychedelic drugs may have their therapeutic qualities due to anti-depressant effects, stimulating neuroplasticity and long-term psychological changes. 2 Abstract Psychedelic drugs have been used as treatments in indigenous cultures for thousands of years. Yet, due to their legal status, there has been limited scientific research into the therapeutic potential of these compounds for psychiatric disorders. In the absence of other effective treatments however, researchers have begun again to systematically investigate such compounds and there is now evidence pointing to the use of psychedelic drugs in the treatment of addiction. In this review we focus on human evidence for the effectiveness of preparations used by indigenous cultures in the Amazon (ayahausca) and Africa (ibogaine) and worldwide (psilocybin), and more recently synthetised drugs such as the serotonergic hallucinogen LSD and the dissociative anaesthetic ketamine. -
Journal of Museum Studies, Volume 8, Number 1 Journal of Museum Studies
THE UNIVERSITY OF OKLAHOMA COLLEGE OF LIBERAL STUDIES CLS Journal of Museum Studies, Volume 8, Number 1 Journal of Museum Studies e-Journal of the Museum Studies Program VOL 8 | NO 1 | DEC 2014 Foreword The Breadth of Natural History Research by Michael A. Mares Talking God and Father Peyote: Preliminary Quantification of Curator Religious Pluralism and Contemporary Diné Success in Life Science Natural History (Navajo) Art Collections by Daniel C. Swan and Dakota H. Stevens by Jessa L. Watters and Cameron D. Siler Edited by Michael A. Mares CLS Journal of Museum Studies, Volume 8, Number 1 CLS Journal of Museum Studies, Volume 8 Number 1 (Dec. 2014) http://jms.ou.edu CLS Journal of Museum Studies is currently published online by the College of Liberal Studies, MALS Museum Studies Program, the University of Oklahoma. Your use of the CLS Journal of Museum Studies archives indicates your acceptance of the Terms and Conditions of Use, available at http://jms.ou.edu. Museum professionals, students, and other readers are encouraged to distribute the articles published in this journal as widely as possible, to use them in classes, and to reprint them as needed. For commercial use of any of these articles Cover Photograph: Mother Earth, Father Sky and the Yeis (e.g., charging for articles, republishing figures, tables, text, etc.), Dancers, 2006. Jackie Black, Diné (Navajo), Red Valley, New permission must be obtained from the Editor. All questions Mexico. Acrylic on canvas. Sam Noble Museum. relating to the journal should be directed to the Editor. Journal Editor Publisher contact information available at http://jms.ou.edu. -
Native American Church
Native American Traditions Native American Church Native American Church Summary: The Native American Church of Jesus Christ is a spiritual movement that integrates the teachings of Christian life with the spiritual and ethical traditions of various Native cultures. A central component of the Native American Church is the sacramental ingestion of peyote during peyote meetings. In 1990, the U.S. Supreme Court has ruled that the ritual ingestion of peyote is not a legally protected practice, despite its religious significance. The Native American Church of Jesus Christ is the full name of a widespread spiritual movement that integrates the teachings of Christian life with the spiritual and ethical traditions of various Native cultures regarding the sacramental ingestion of peyote. For some participants, the Christian context is important, but for others the Native American Church is much more an affirmation of Indian religious identity. While the visionary effect of the peyote cactus button has captured the imagination of many psychedelic spiritual seekers, it is critical that those who would understand the ceremonial use of peyote situate this sacramental tradition within the rigorous ethical way of life taught by the Native American Church. Many church members believe that a narrow perception of peyote as simply an hallucinogen or “drug” informed the U.S. Supreme Court’s 1990 decision in Employment Division of Oregon v. Smith. In the Smith case, two Native Americans had been fired from their state jobs in Oregon because they participated in a peyote ceremony of the Native American Church. Peyote had been listed as a proscribed drug in the state. -
A Review of a Culture's Catalyst: Historical Encounters with Peyote and the Native American Church in Canada
IK: Other Ways of Knowing Book Review A Review of A Culture’s Catalyst: Historical Encounters with Peyote and the Native American Church in Canada Book Review by Kevin Feeney PhD. JD, Central Washington University A Culture’s Catalyst: Historical Encounters with Peyote and the Native American Church in Canada by Kahan, Fannie, edited by Erika Dyck. 2016. Winnipeg, MB: University of Manitoba Press. 130 pp. Paperback $27.95. ISBN 978-0887558146 doi 10.18113/P8ik360543 Fannie Kahan’s new book, A Culture’s Catalyst, provides a novel glimpse into an era when psychedelic research was at its peak, and when social fears about psychedelics were limited to the imagined orgies of peyote cults. Kahan’s original manuscript was completed back in 1963, but failed efforts at finding a publisher left the book gathering dust in the archives of the author’s brother, Abram Hoffer. The manuscript remained buried in papers until it was uncovered by historian Erika Dyck during investigations on the history of psychedelic research in Canada. Dyck has brought this manuscript to light by editing it for clarity and uniformity, and providing an in-depth introduction contextualizing Kahan’s work within the political landscape of the 1950s and early 1960s. Kahan’s book is largely built around a Native American Church peyote ceremony held during 1956 in North Battleford, Sasketchewan. A handful of White scientists attended the ceremony, including book contributors Duncan Blewett, Abram Hoffer, Humphry Osmond, and Teodoro Weckowicz. Kahan, who is a journalist by training, has assembled and presented what might best be characterized as a defense of peyotism, the religious use of peyote, with a text that veers between reporting and editorializing. -
A Long Strange Trip: Latin America's Contribution to World Drug Culture
e l e v e n A Long Strange Trip latin america’s contribution to world drug culture Paul Gootenberg Perhaps it’s risky, even foolhardy, for a historian to suggest that drugs are one of Latin America’s enduring contributions to world culture. Today, “drugs” mostly conjures up cocaine, meth, addiction, corruption, traf- fickers, DEA drug wars, and the unfathomably brutal bloodletting along the northern borders of Mexico. It also suggests the unfortunate tendency of (North) Americans to blame their intemperate desires for consuming drugs on evil foreigners, the Pablo Escobars and Chapo Guzmáns, or wily “cartels” (a term that makes specialists cringe). It also serves to sweep under the rug the complicity of our institutions and badly conceived drug laws and policies— namely, global drug prohibition—in igniting the kinds of mayhem that have afflicted places like Colombia, Peru, and Mexico in recent decades. So, here, I’d like to step back and suggest as a corrective a few less sensationalistic, less ahistorical, less U.S.-centric points: the richer, longer cornucopia of mind- altering goods the Americas have offered the world; some of the changing historical entanglements of these drugs with global culture; and, most recently, promising new shifts, coming from the Global “South,” on how to rethink our bellicose current posture on illicit drugs. This long trip through hemispheric drugs is rich in historical ironies. psychedelic civilizations Thousands of years ago, prehistoric Americans invented what the ethnobota- nist Winston LaBarre termed the “American drug complex,” the world’s wid- est and wildest menu of psychotropic drugs. -
Neuropsychedelia
Neuropsychedelia The Revival of Hallucinogen Research since the Decade of the Brain Nicolas Langlitz UNIVERSITY OF CALIFORNIA PRESS Berkeley • Los Angeles • London Contents. University of California Press, one of the most distinguished university presses in the United States, enriches lives around the world by advancing scholarship in the humanities, social sciences, and natural sciences. Its activities are supported by the UC Press Foundation and by philanthropic contributions from individuals and institutions. For more information, visit www.ucpress.edu. University of California Press Berkeley and Los Angeles, California University of California Press, Ltd. London, England © 2013 by The Regents of the University of California Acknowledgments Vtl Library of Congress Cataloging-in-Publication Data Introduction: Neuropsychopharmacology Langlitz, Nicolas, 1975-. Neuropsychedelia : the revival of hallucinogen as Spiritual Technology I research since the decade of the brain I Nicolas Langlitz. 1. Psychedelic Revival p. cm. Includes bibliographical references and index. 2. Swiss Psilocybin and US Dollars 53 ISBN 978-0-520-27481-5 (cloth: alk. paper) ISBN 978-0-520-27482-2 (pbk. : alk. paper) 3. The Varieties of Psychedelic Lab Experience I. Hallucinogenic drugs-Research. 2. Neuropsychopharmacology. 3. Hallucinogenic 4. Enacting Experimental Psychoses 2 drugs and religious experience. 1. Title. I3 BF209·H34L36 2013 - I54·4-dc23 5. Between Animality and Divinity I66 2012022916 6. Mystic Materialism 2°4 Manufactured in the United States of America Conclusion: Fieldwork in Perennial Philosophy 243 21 20 19 18 17 16 15 14 13 10 9 8 7 6 5 4 3 2 In keeping with a commitment to support Notes environmentally responsible and sustainable printing practices, UC Press has printed this book on 50-pound Bibliography Enterprise, a 30% post-consumer-waste, recycled, Index deinked fiber that is processed chlorine-free. -
Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans
molecules Review Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans Paul Cumming 1,2,* , Milan Scheidegger 3 , Dario Dornbierer 3, Mikael Palner 4,5,6 , Boris B. Quednow 3,7 and Chantal Martin-Soelch 8 1 Department of Nuclear Medicine, Bern University Hospital, CH-3010 Bern, Switzerland 2 School of Psychology and Counselling, Queensland University of Technology, Brisbane 4059, Australia 3 Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital of the University of Zurich, CH-8032 Zurich, Switzerland; [email protected] (M.S.); [email protected] (D.D.); [email protected] (B.B.Q.) 4 Odense Department of Clinical Research, University of Southern Denmark, DK-5000 Odense, Denmark; [email protected] 5 Department of Nuclear Medicine, Odense University Hospital, DK-5000 Odense, Denmark 6 Neurobiology Research Unit, Copenhagen University Hospital, DK-2100 Copenhagen, Denmark 7 Neuroscience Center Zurich, University of Zurich and Swiss Federal Institute of Technology Zurich, CH-8058 Zurich, Switzerland 8 Department of Psychology, University of Fribourg, CH-1700 Fribourg, Switzerland; [email protected] * Correspondence: [email protected] or [email protected] Abstract: Hallucinogens are a loosely defined group of compounds including LSD, N,N- dimethyltryptamines, mescaline, psilocybin/psilocin, and 2,5-dimethoxy-4-methamphetamine (DOM), Citation: Cumming, P.; Scheidegger, which can evoke intense visual and emotional experiences. We are witnessing a renaissance of re- M.; Dornbierer, D.; Palner, M.; search interest in hallucinogens, driven by increasing awareness of their psychotherapeutic potential. Quednow, B.B.; Martin-Soelch, C. As such, we now present a narrative review of the literature on hallucinogen binding in vitro and Molecular and Functional Imaging ex vivo, and the various molecular imaging studies with positron emission tomography (PET) or Studies of Psychedelic Drug Action in single photon emission computer tomography (SPECT).